Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.0001
Symbol
ACET on Nasdaq
Shares outstanding
153,881,229
Price per share
$0.52
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
51,335,037
Total reported value
$41,591,047
% of total 13F portfolios
0%
Share change
-268,034
Value change
-$36,555
Number of holders
53
Price from insider filings
$0.52
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 9.6% $11,974,668 14,772,598 ORBIMED ADVISORS LLC 08 Oct 2025
TANG CAPITAL MANAGEMENT LLC 9.9% $6,208,827 8,223,612 TANG CAPITAL MANAGEMENT, LLC 31 Mar 2025

As of 30 Sep 2025, 53 institutional investors reported holding 51,335,037 shares of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET). This represents 33% of the company’s total 153,881,229 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) together control 33% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 7.4% 11,447,140 0% 0.22% $9,274,473
TANG CAPITAL MANAGEMENT LLC 5.3% 8,223,612 0% 0.26% $6,662,770
RA CAPITAL MANAGEMENT, L.P. 4.9% 7,541,000 0% 0.08% $6,109,718
GOLDMAN SACHS GROUP INC 2.4% 3,751,617 -0.01% 0% $3,039,560
VANGUARD GROUP INC 2.1% 3,272,522 0% 0% $2,650,743
Carlyle Group Inc. 1.9% 2,948,718 0% 0.06% $2,388,756
ACADIAN ASSET MANAGEMENT LLC 1.5% 2,265,491 +9.2% 0% $1,835,000
RENAISSANCE TECHNOLOGIES LLC 1.2% 1,828,949 +59% 0% $1,481,814
REGENERON PHARMACEUTICALS, INC. 0.63% 968,183 0% 0.11% $784,422
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.59% 901,600 0% 0.02% $730,476
TWO SIGMA INVESTMENTS, LP 0.56% 854,568 +67% 0% $692,371
TWO SIGMA ADVISERS, LP 0.51% 780,982 +38% 0% $632,752
GEODE CAPITAL MANAGEMENT, LLC 0.46% 706,334 0% 0% $572,440
Alyeska Investment Group, L.P. 0.43% 655,665 0% 0% $531,220
RBF Capital, LLC 0.4% 617,319 0% 0.02% $500,152
BlackRock, Inc. 0.38% 585,377 -2.4% 0% $474,272
CITADEL ADVISORS LLC 0.38% 583,948 +27% 0% $473,115
MILLENNIUM MANAGEMENT LLC 0.37% 565,953 -4.5% 0% $458,535
Schonfeld Strategic Advisors LLC 0.31% 479,108 -75% 0% $388,171
JOHNSON & JOHNSON 0.24% 364,472 0% 0.06% $295,295
WEALTHEDGE INVESTMENT ADVISORS, LLC 0.19% 300,054 -4.2% 0.09% $243,104
BARCLAYS PLC 0.19% 300,000 +100% 0% $243,060
STATE STREET CORP 0.16% 244,186 -1.1% 0% $197,840
JANE STREET GROUP, LLC 0.12% 186,200 0% $150,859
NORTHERN TRUST CORP 0.09% 140,373 0% 0% $113,730

Institutional Holders of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 51,335,037 $41,591,047 -$36,555 $0.81 53
2025 Q2 51,603,071 $31,484,026 -$3,114,221 $0.61 47
2025 Q1 55,856,035 $42,041,103 -$1,434,569 $0.76 56
2024 Q4 57,616,208 $55,430,722 -$613,083 $0.96 61
2024 Q3 57,126,257 $82,259,457 -$8,520,911 $1.44 62
2024 Q2 63,950,445 $77,407,916 -$23,984,627 $1.21 83
2024 Q1 75,135,656 $176,537,613 +$98,192,610 $2.35 96
2023 Q4 33,363,531 $63,033,300 -$3,182,870 $1.89 76
2023 Q3 35,675,697 $48,851,768 -$4,181,891 $1.37 83
2023 Q2 37,121,626 $90,180,708 -$28,161,740 $2.43 92
2023 Q1 40,249,929 $231,250,449 -$1,583,181 $5.76 105
2022 Q4 42,143,638 $376,757,638 -$18,208,642 $8.94 100
2022 Q3 41,668,911 $592,464,001 +$53,381,880 $14.22 98
2022 Q2 37,871,013 $553,032,820 +$48,530,334 $14.60 97
2022 Q1 33,013,038 $659,188,374 +$43,094,111 $19.97 82
2021 Q4 30,385,666 $531,158,057 +$190,514,360 $17.49 78
2021 Q3 19,920,035 $156,119,000 -$14,652,181 $7.84 54
2021 Q2 21,191,598 $218,012,000 +$7,951,899 $10.29 60
2021 Q1 20,347,324 $265,987,000 +$141,427,052 $13.08 50
2020 Q4 9,536,513 $133,985,000 +$6,730,351 $14.05 39
2020 Q3 9,051,029 $107,615,000 +$107,615,000 $11.89 28